Lab-Grown tumors may pick best drug for bladder cancer patients
NCT ID NCT07379268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses lab-grown mini-tumors (organoids) from bladder cancer patients to see which anti-HER-2 drug works best. It compares survival rates of patients whose treatment is guided by these organoids versus standard protein testing. The goal is to improve one-, two-, and three-year survival for people with advanced bladder cancer who have already tried chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qilu Hospital of Shandong University
RECRUITINGJinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Can One-Piece tumour removal improve bladder cancer outcomes?